Ramon Sebastian Leon-Zetina, Laura Romero-Romero, Marina Guadarrama-Olhovich and Patricia Garcia-Lopez
National Institute of Cancerology, Mexico
Posters & Accepted Abstracts: J Cancer Sci Ther
Glioblastoma multiforme is the most aggressive malignant central nervous system neoplasm and is classified
as grade IV in the WHO most recent neuropathological classification schemes. Treatment is composed by
combination of radiotherapy and chemotherapy, however, even with treatment, survival time is low (12-16 months)
besides that glioblastoma has chemoresistance to Temozolomide (Tz). Recent research has showed that Mifepristone
(Mf) increase cytotoxicity of several antineoplastic agents, including Tz during Glioblastoma treatment, nevertheless
there is no preclinical safety (toxicity) studies including a combination of both drugs; therefore, the objective of this
project is to evaluate the toxicity preclinically which is necessary for its use in clinic. Acute toxicity and local tissue
damage test were done in male Wistar rats, Specific Pathogen Free (SPF) divided in three groups: 1) Tz, 2) Tz-Mf
and 3) control group. The rats were administered by 21 days. During the chemotherapy administration, three blood
sampling where obtained for cell blood count (CBC) and biochemistry. After 21 days, animal postmortem study was
done as well as histopathological evaluation focusing on organs with toxicological importance. Also, genotoxicity
evaluation was carried out using in-vivo model (micronucleus essay) in which ICR SPF mice were used and divided
in three groups: 1) Cyclophosphamide, 2) Tz-Mf, 3) negative control. Blood sampling were done at 36 and 72 hours
after drug administration. Results in both studies suggest no evidence of toxicity in Tz and Mf combination that
prevents its use for Glioblastoma treatment.
1. Fusocelular Sarcoma and thoracic metastasis, REMEVET, Small animal oncology special edition, #30, year 8, 2017 ISNN2017-3933.
Ramón Sebastián Leon-Zetina is a Doctor in Veterinary Medicine and Pathologic Diagnostic Specialist. Currently, he is pursuing his Master’s at Universidad Nacional Autónoma de México, Instituto Nacional de Cancerología Mexico City, Mexico. He has 4 years of experience in laboratory animal pathology in diagnostic and research fields (toxicity and animal model studies) and has worked in Glioblastoma research for two years.
E-mail: [email protected]
Cancer Science & Therapy received 3358 citations as per Google Scholar report